Developing targeted therapies for patients living with rare and aggressive diseases

Ayala is a clinical-stage pharmaceutical company developing precision therapies for genetically defined cancers. The Company is developing two small molecule drugs that inhibit a genetic mutation known as Notch which plays a role in tumor proliferation. Ayala has initiated Phase II trials in Adenoid Cystic Carcinoma and Triple-Negative Breast Cancer, two orphan indications with a definable subset of patients that harbor these notch mutations. The Company is also co-developing a combination therapy with Novartis for Multiple Myeloma.

Investing partner / fund: